Observational studyFrontiers in immunology2026

Adjuvant disitamab vedotin plus PD-1 blockade and gemcitabine/cisplatin in high-risk upper tract urothelial carcinoma: a two-stage real-world comparative study.

Cheng Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.